Q&A: Antibiotic resistance: where does it come from and what can we do about it? by Wright, Gerard D
Is antibiotic resistance inevitable?
Yes. Historically, the discovery of the sulfa drugs in the 
1930s  and  the  subsequent  development  of  penicillin 
during  World  War  II  ushered  in  a  new  era  in  the 
treatment  of  infectious  diseases.  Infections  that  were 
common causes of death and disease in the pre-antibiotic 
era  -  rheumatic  fever,  syphilis,  cellulitis  and  bacterial 
pneumonia - became treatable, and over the next 20 years 
most  of  the  classes  of  antibiotics  that  find  clinical  use 
today  were  discovered  and  changed  medicine  in  a 
profound  way.  The  availability  of  antibiotics  enabled 
revolu  tionary  medical  interventions  such  as  cancer 
chemo  therapy, organ transplants and essentially all major 
invasive  surgeries  from  joint  replacements  to  coronary 
bypass. Antibiotics, though, are unique among drugs in 
that their use precipitates their obsolescence. Paradoxi-
cally,  these  cures  select  for  organisms  that  can  evade 
them, fueling an arms race between microbes, clinicians 
and drug discoverers.
How do successful antibiotics work and what is the 
basis of resistance to them?
Antibiotics target essential bacterial physiology and bio-
chemistry, causing microbial cell death or the cessation 
of  growth.  There  are  five  major  antibiotic  targets:  the 
bacterial cell wall, the cell membrane, protein synthesis, 
DNA  and  RNA  synthesis,  and  folic  acid  (vitamin  B9) 
metabolism (Figure 1). These bacterial targets are differ-
ent or nonexistent in eukaryotic cells (including those of 
humans),  which  means  that  antibiotics  are  relatively 
nontoxic  drugs.  For  example,  the  β-lactam  antibiotics 
such  as  penicillins,  cephalosporins  and  carbapenems 
block  the  synthesis  of  the  bacterial  cell  wall.  This 
structure is absent in higher organisms but is essential for 
bacterial survival. The bacterial ribosome is the target of 
the  tetracycline,  aminoglycoside,  macrolide  and  other 
antibiotics,  and  is  sufficiently  different  from  the 
eukaryotic ribosome that cross-inhibition does not occur.
Resistance to antibiotics occurs through four general 
mechanisms:  target  modification;  efflux;  immunity  and 
bypass;  and  enzyme-catalyzed  destruction  (Figure  1). 
Target modification can occur through mutation of the 
targets themselves - for example, the topoisomerases that 
are the target of the fluoroquinolone antibiotics - or by 
the production of enzymes that modify antibiotic targets, 
as, for example, in ribosomal methylation. Vancomycin 
resistance is a version of target modification where new 
biosynthetic  machinery  is  engaged  to  alter  cell-wall 
structure. Efflux occurs through a large family of protein 
pumps  that  eject  antibiotics  from  inside  the  cell.  In 
immunity,  antibiotics  or  their  targets  are  bound  by 
proteins that prevent the antibiotic binding to its target. 
Arguably, the most specific and evolved mechanism of 
antibiotic  resistance  are  enzymes  that  recognize  anti-
biotics and modify them in such a way as to eliminate the 
functional  characteristics  that  enable  them  to  interact 
with  their  targets.  For  example,  β-lactamases  hydro-
lytically cleave the core β-lactam ring that is characteristic 
of the class and essential to antibiotic action.
Has the problem of antibiotic resistance worsened 
over time?
Resistance to antibiotics was recorded even before the 
first clinical use of penicillin in the early 1940s. In the 
intervening years, resistance to all classes of antibiotics 
has  emerged,  and  there  are  no  antibiotics  for  which 
resistance does not exist. There are two general strategies 
for resistance. One comprises mechanisms that transfer 
resistance  vertically  from  a  bacterium  to  its  progeny. 
Examples are mutations in chromosomal genes that give 
rise  to  drug-insensitive  products,  such  as  the  point 
mutations in the genes encoding DNA gyrase or topo-
isomerase IV that result in resistance to fluoroquinolone 
antibiotics  such  as  ciprofloxacin.  The  second  strategy 
includes  the  actions  of  genes  that  can  be  transmitted 
both  vertically  to  progeny  and  horizontally  to  other 
bacteria, even those of different genera. These genes are 
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which can carry one or more resistance genes. Many of 
the  β-lactamase  genes  that  confer  resistance  to  the 
penicillin,  cephalosporin,  penem  and  monobactam 
antibiotics  are  located  on  such  elements,  as  is  the 
glycopeptide-resistance  gene  cluster  vanHAX,  which 
provides resistance to vancomycin. The prevalence and 
mobility  of  resistance  genes  in  previously  sensitive 
pathogenic bacteria has now reached crisis levels in many 
cases  because  new  antibiotics  are  no  longer  being 
developed  at  a  rate  that  can  keep  pace  with  microbial 
evolution.
In the past two decades we have witnessed:
•	 the	rise	of	so-called	extended	spectrum	β-lactamases	
(ESBLs), which are mutants of enzymes that previously 
could only inactivate penicillins but now have gained 
activity against many cephalosporins;
•	 carbapenemases	 such	 as	 KPC	 and	 NDM-1	 that	
inactivate all β-lactam antibiotics;
•	 plasmid-mediated	(and	thus	horizontally	disseminated)	
resistance to fluoroquinolone antibiotics;
•	 the	 spread	 of	 virulent	 MRSA	 (methicillin-resistant	
Staphylococcus aureus) in the community;
•	 the	rise	of	multi-drug	resistant	Neisseria gonorrhoea;
•	 the	emergence	and	global	dissemination	of	multi-drug	
resistant Acinetobacter baumannii, Pseudomonas aerugi­
nosa, Klebsiella pneumoniae and Enterobacteriaceae;
•	 the	spread	of	extensively	drug	resistant	Mycobacterium 
tuberculosis;
•	 the	 development	 of	 resistance	 to	 the	 two	 newest	
antibiotics to be approved for clinical use - daptomycin 
and linezolid.
Resistance is relentless and unavoidable as long as we use 
antibiotics.
Where does resistance come from?
Antibiotic resistance is the evolutionary response to the 
strong selective pressure that results from exposure to 
these  compounds.  The  horizontal  dissemination  of 
resistance genes into bacterial species and genera that are 
not  themselves  intrinsically  resistant,  as  well  as  the 
maintenance of resistance mutations vertically through 




























































































Wright BMC Biology 2010, 8:123 
http://www.biomedcentral.com/1741-7007/8/123
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of these drugs in the clinic and on the farm. Support for 
this hypothesis is the infrequency of antibiotic resistance 
in  collections  of  pathogenic  bacteria  that  pre-date  the 
antibiotic era.
Nevertheless,  antibiotic  resistance  is  a  natural 
phenomenon. It has been recognized for decades that the 
resistance mechanisms that have emerged in the clinic 
parallel  those  that  are  intrinsic  to  the  bacteria  that 
produce  antibiotics.  Recent  studies  of  non-pathogenic 
soil  bacteria  have  revealed  that  the  majority  of 
environmental  bacteria  tested  are  multi-drug  resistant. 
This reflects the fact that these microbes live and have 
evolved  in  an  environment  where  small  bioactive 
molecules,  some  toxic,  some  benign,  are  plentiful  and 
diverse.  Bacteria  have  simply  evolved  to  interact  with 
them and control their biological effects. Pathogens, on 
the  other  hand,  are  often  more  virulent  forms  of  our 
commensal bacteria and simply have not been exposed to 
the diversity and types of small molecules found in the 
environment;  as  a  result,  they  have  not  required  the 
gamut of resistance genes found in some environmental 
bacteria.
Furthermore,  the  genes  and  proteins  responsible  for 
resistance in environmental bacteria are homologous to 
those found circulating in pathogens, strongly suggesting 
contemporary  horizontal  gene  transfer.  Opportunistic 
pathogens with environmental reservoirs - for example, 
P.  aeruginosa  and  A.  baumannii  -  are  highly  drug 
resistant and have a remarkable capacity to acquire new 
resistance  genes.  The  environment  is  therefore  a  large 
reservoir of potential resistance genes: the environmental 
‘resistome’.
Given the vast numbers of bacteria on the planet and 
the  massive  selection  pressure  provided  by  antibiotics, 
the  movement  of  antibiotic-resistance  elements  from 
benign, but resistant, microbes into previously suscep-
tible  pathogens  is  simply  a  matter  of  time  and 
opportunity.
Can anything be done to slow down the emergence 
of resistance?
Antibiotics themselves are the source of the evolutionary 
pressure that eventually renders them obsolete. Limiting 
exposure of microbes to antibiotics therefore makes good 
sense  to  reduce  the  opportunity  for  the  selection  and 
dissemination  of  resistance.  The  inappropriate  use  of 
antibiotics by clinicians and the agricultural community 
needs to be curtailed. Over the past several years, the 
medical  community  in  particular  has  made  concrete 
efforts  to  curb  the  improper  use  of  antibiotics.  The 
European Union has taken the lead in limiting the non-
therapeutic  use  of  antibiotics  in  food  animals.  Robust 
surveillance networks that span the clinic and the farm 
need to be supported in order to monitor the impact of 
resistance and the emergence of new threats in real time. 
In  North  America,  efforts  such  as  the  Strategies  to 
Address Antimicrobial Resistance Act seek to diminish 
antibiotic  use  in  agriculture  and  improve  surveillance. 
Furthermore,  there  have  been  several  successful  cam-
paigns to educate the public on the importance of anti-
biotics and the proper use of these drugs. While none of 
these efforts is perfect, there is much to be celebrated and 
encouraged.
These measures all serve to reduce antibiotic use and, 
as a result, delay the emergence of resistance. Further-
more, by decreasing selection pressure, the opportunity 
for  the  rise  of  particularly  clinically  challenging  or 
virulent organisms should be lessened. All strategies that 
reduce the incorrect use of antibiotics are welcome, but 
in the end new drugs will always be needed because of 
the inevitability of resistance.
Unfortunately,  in  the  developing  world,  access  to 
antibiotics is frequently not regulated and their use in 
agriculture is often rampant. These facts make antibiotic 
stewardship  especially  challenging.  In  an  era  of  rapid 
intercontinental  travel,  pathogens  are  no  longer 
geographically contained and can move from country to 
country  with  ease.  The  recent  examples  of  transconti-
nental spread of the severe acute respiratory syndrome 
(SARS)	 virus	 from	 Guangdong	 province	 in	 China	 to	
Hong	Kong	and	then	Canada	in	2003,	and	the	NDM-1	
carbapenemase, which inactivates all β-lactam antibiotics 
and appears to have originated in the Indian subcontinent 
but	is	now	found	in	North	America,	the	UK	and	Europe,	
make the point.
What about new antibiotics?
The  growing  problem  of  resistance  fuels  a  continuous 
need  for  new  antibiotic  drugs.  The  enterobacteria  that 
produce  carbapenemase  are  just  one  example  of 
antibiotic-resistant enterobacteria. Other Gram-negative 
pathogens  resistant  to  virtually  all  antibiotics  include 
multi-drug resistant A. baumannii and P. aeruginosa. The 
expanding problem of MRSA, and the global challenge of 
extensively  drug-resistant  M.  tuberculosis  (also  called 
extreme  drug-resistant  M.  tuberculosis),  require  new 
therapies.
There  are  some  promising  new  candidates  on  the 
horizon, especially for the treatment of infections caused 
by  Gram-positive  pathogens  such  as  MRSA  and 
enterococci. As already mentioned, two new drugs active 
against  this  microbial  spectrum  -  daptomycin  and 
linezolid  -  have  been  introduced  in  the  past  decade. 
Tigecycline,  a  third-generation  semi-synthetic  tetracy-
cline antibiotic approved in 2005, also has activity against 
MRSA.  The  semi-synthetic  glycopeptide  antibiotic 
telavancin recently received approval in the United States 
Wright BMC Biology 2010, 8:123 
http://www.biomedcentral.com/1741-7007/8/123
Page 3 of 6and  the  fifth-generation  cephalosporin  ceftobiprole  is 
available	 in	 some	 European	 countries	 and	 Canada.	
However,  there  are  few  candidates  in  late-stage  clinical 
trials suitable for the problem of Gram-negative pathogens. 
Here, often the choice of last resort is colistin, an antibiotic 
discovered more than 50 years ago and seldom used in the 
past because of adverse affects, including kidney toxicity; 
however, it is now increasingly used.
Why are there so few new drugs?
There are a number of reasons, some economic, for the 
paucity of new antibiotics. They include challenging and 
shifting  processes  of  government  regulatory  approval 
that  add  to  the  risk  for  the  pharmaceutical  industry. 
Furthermore,  considerations  of  return  on  investment 
favor  drugs  for  chronic  diseases,  which  are  taken  by 
patients  over  long  periods  of  time,  often  decades.  In 
contrast, antibiotics cure disease and are taken for short 
periods of time.
Other  reasons  for  the  decline  in  antibiotic  discovery 
and  development  are  scientific.  The  first  wave  of 
antibiotics discovered five decades ago have been termed 
the ‘low hanging fruit’. Despite the discovery of numerous 
compounds with antibiotic properties in the years since, 
few have had the requisite properties to become drugs. 
Most antibiotics are natural products or their derivatives 
that  have  been  isolated  from  soil  bacteria.  Some 
researchers have suggested that this source might now be 
exhausted.
Furthermore, the promise of the genomic era and the 
reality of hundreds of available bacterial genomes have so 
far failed to deliver the hoped-for new molecular targets 
for  antibiotics.  Other  new  technologies,  such  as  high-
throughput screening of libraries of synthetic molecules, 
have not resulted in new drugs, although this may reflect 
a  poor  choice  of  chemical  classes  in  the  screens, 
emphasizing  molecules  more  active  in  human  biology 
than as antibiotics. Test compounds were often skewed 
in  favor  of  small  lipophilic  molecules  with  physical 
properties  meeting  the  criteria  of  Lipinski’s  Rule  of  5. 
However, though helpful in assessing the prospect of a 
compound to be an orally active drug for human disease, 
this strategy has been shown to fail when searching for 
antibiotics.
So what would be suitable chemical matter for leads?
Well,  natural  chemicals  have  significant  advantages. 
Although the first antibiotics introduced into the clinic 
were  the  synthetic  sulfonamides,  the  majority  of 
antibiotics in current clinical use are bacterially produced 
natural  products  or  their  derivatives;  only  a  few  are 
completely  synthetic  in  origin.  The  reasons  for  this  in 
part  reflect  the  history  of  antibiotic  discovery  post-
penicillin, and the relative ease of discovery of suitable 
molecules  through  screening  the  products  of  soil 
microbes  compared  with  libraries  of  synthetic  com-
pounds. Many of these ‘natural’ antibiotics have desirable 
drug-like qualities, such as good bioavailability, the ability 
to cross the cell membrane (and outer membrane in the 
case of compounds with Gram-negative activity) and the 
ability to evade efflux systems, and chemical structures 
that favor binding to vital cellular targets, supporting the 
idea  that  natural  products  encompass  privileged 
structures  in  antibiotic  drug  discovery.  However,  the 
increasing  difficulty  of  identi  fying  new  chemical 
compounds with equally suitable drug-like characteristics 
from natural sources has caused natural-product-based 
screening  programs  to  fall  out  of  favor  in  many 
pharmaceutical firms over the past few decades.
Instead,  the  ability  of  parallel  synthesis  methods  to 
generate hundreds of thousands of synthetic molecules 
suitable  for  modern  high-throughput  screening  has 
shifted  the  focus  in  favor  of  synthetic  molecules  in 
commercial antibacterial drug discovery. The advantages 
of synthetic compounds are not insignificant: pure lead 
molecules can easily be produced in quantity and quality 
suitable  for  clinical  trials,  and  are  relatively  easily 
modified to improve target affinity. However, after two to 
three  decades  of  emphasis  on  such  molecules  and 
millions of dollars spent on high-throughput in vitro and 
cell-based  screens,  no  new  synthetic  antibiotics  have 
emerged.  Linezolid,  the  one  synthetic  antibiotic  to  be 
brought  to  market  in  the  past  decade,  was  discovered 
using  traditional  medicinal  chemistry  in  a  research 
program with a plant-disease focus in the early 1980s.
So does that mean natural products are best 
after all?
They  do  have  great  advantages,  although  a  direct 
comparison  of  the  success  and  failure  of  synthetic  as 
against  natural  product  libraries  is  unfair.  Microbial 
natural products have evolved over millennia to interact 
with  biological  molecules,  whereas  the  synthetic 
chemical  libraries  used  in  antibiotic  drug-discovery 
screens were generally developed with a focus on eukary-
otic drug-discovery campaigns, as noted earlier. Efforts 
to develop physical-property rules for antibiotics and to 
incorporate natural-product-like chemical complexity in 
libraries  of  synthetic  chemicals  will  no  doubt  improve 
success in identifying new synthetic antibiotic leads.
Ironically,  at  the  same  time  that  the  pharmaceutical 
industry was abandoning natural-product libraries, uni-
versity researchers were making remarkable advances in 
understanding the molecular details of natural-product 
biosynthesis  by  bacteria.  Many  bacteria,  especially  the 
actinomycete group of common environmental bacteria, 
are prodigious producers of natural products. These are 
termed secondary metabolites to contrast with molecules 
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acids  and  so  on.  Secondary  metabolites  range  in 
molecular weight from around 100 daltons (Da) to up to 
5,000  Da  and  they  have  diverse  biological  activities, 
including  induction  of  cell  death  (antibiotics  such  as 
tetracycline, vancomycin and daptomycin, and anticancer 
agents  such  as  adriamycin),  iron  sequestration  (for 
example, enterobactin), facilitation of cell-cell communi-
cation  (γ-butyrolactones),  protection  from  oxidizing 
agents (phenazines), and a host of others.
The bacterial natural products that are most important 
as antibiotics include polyketides, such as the macrolides 
and tetracyclines, and non-ribosomal peptides - that is, 
peptides that are not synthesized on ribosomes - which 
include β-lactams and glycopeptides such as vancomycin. 
These are produced in the cell in assembly-line fashion 
on large dedicated enzyme platforms called, respectively, 
polyketide  synthases  and  non-ribosomal  peptide  syn-
thetases.  Following  assembly  the  compounds  are  then 
‘decorated’  by  a  series  of  modifying  enzymes,  such  as 
glycosyltransferases. The end result is a molecule of often 
complex  structure,  with  multiple  chiral  centers  and 
functional groups such as sugars, halogens, sulfates, acyl 
groups and others.
In general, bacterial genes that encode the production 
of natural products are clustered together in the genome, 
greatly facilitating analysis and prediction of biosynthetic 
pathways  and  structures.  Indeed,  several  software 
packages (for example, NP.searcher) have been developed 
based on rules-based understanding of natural-product 
biosynthesis.  The  availability  of  cheap,  rapid  genome 
sequen  cing  means  that  time-consuming  construction 
and  screening  of  gene  libraries  for  natural-product 
clusters can now be bypassed. Genome sequencing has 
also  revealed  a  hitherto  unrealized  richness  in  the 
quantity and variability of natural-product biosynthetic 
clusters. Sequenced genomes of bacteria of the actino-
mycetes class reveal 20 to 30 biosynthetic clusters in each 
organism.  Furthermore,  natural-product  producing 
bacteria from non-soil environments are being investi-
gated and these have already resulted in new chemical 
matter,  suggesting  that  there  is  a  fantastic  wealth  of 
untapped  chemical  diversity  waiting  to  be  discovered. 
Perhaps some of this diversity will include new antibiotic 
chemical scaffolds.
We are in a remarkably productive time for natural-
product research that is serving to reinvigorate interest in 
this sector. At the same time, the application of synthetic 
biology approaches to this field could serve to improve 
issues of yield and expand chemical diversity.
Are there alternatives to new antibiotics?
Yes.  First,  existing  discarded  antibiotics  can  be  re-
examined. The development of daptomycin is instructive. 
Daptomycin was discovered by the antibiotic group at Eli 
Lilly in the 1980s, but was not fully developed because of 
toxicity  concerns.  The  antibiotic  was  obtained  by 
researchers	at	Cubist	in	1997	and	by	altering	the	dosing,	
this group was able to bring the antibiotic to market in 
2003,  since  when  it  has  proved  highly  successful  in 
treating infections caused by Gram-positive pathogens. 
Certainly,	there	are	other	‘old’	antibiotics	discovered	by	
the  pharmaceutical  industry  but  not  developed  at  the 
time that could be resurrected as leads for new drugs.
A second option is the combination of antibiotics with 
each  other  and  with  other  drugs  to  improve  efficacy. 
Infectious-disease  physicians  often  combine  antibiotics 
in an effort to achieve synergy, and this well-established 
practice has resulted in formulated drug combinations, 
such as co-trimoxazole (trimethoprim and sulfa  methoxa-
zole).	 Combination	 of	 antibiotics	 with	 non-antibiotics	
deserves investigation as well. Several natural products 
have  been  discovered  by  Satoshi  Omura’s  group  that 
potentiate the activities of antibiotics such as imipenem 
in S. aureus by unknown mechanisms.
Other antibiotic adjuvants are inhibitors of resistance 
mechanisms.  The  tremendous  commercial  and  clinical 
success  of  Augmentin  (ampicillin  together  with  the  β-
lactamase  inhibitor  clavulanic  acid)  and  other  similar 
combinations speaks to the power of such combinations. 
Our  growing  understanding  of  the  mechanisms  of 
resistance  should  fuel  such  approaches.  Inhibitors  of 
efflux  pumps,  for  example,  have  been  discovered,  and 
though  challenging  to  implement  in  organisms  with 
multiple  redundant  systems,  are  worthy  of  continued 
investigation.
Finally, other strategies orthogonal to antibiotics must be 
on the table. We should never forget vaccines as proven 
and  outstanding  protective  agents  against  infectious 
diseases.  Bacterial  viruses  (bacteriophages)  were  used 
extensively to treat bacterial infections in the former Soviet 
Union  and  could  find  new  application  in  the  face  of 
outbreaks  of  multi-drug  resistant  bacteria,  especially  in 
settings such as hospital infections. The use of enhancers 
of  innate  immunity,  such  as  cationic  antimicrobial 
peptides, is also an approach worth investigating.
What is the outlook for new drugs and further 
resistance?
We need antibiotics to maintain our current standard of 
health  care.  As  already  stated,  resistance  is  a  natural 
evolutionary  phenomenon  that  cannot  be  stopped. 
Through  judicious  use  of  current  drugs  and  the 
development  of  new  ones,  the  pace  of  resistance 
development  can  be  controlled  without  impairing  our 
ability  to  control  disease.  The  need  for  new  drugs  is, 
however, acute. Antimicrobial stewardship alone cannot 
fulfill our requirement for new antibiotics.
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research  in  antibiotics.  The  rapidity  of  genome 
sequencing,  the  maturing  of  our  knowledge  of  natural 
product  biosynthesis,  a  growing  understanding  of  the 
physical properties of ideal antibiotics, the development 
of new strategies to develop synthetic compounds with 
improved  antibiotic  properties,  and  the  possibilities  of 
synthetic biology combine to suggest that we are entering 
a  highly  productive  period  of  antibiotic  discovery.  The 
challenges of moving these advances into the clinic fast 
enough to keep pace with resistance are significant, but 
with  concerted  effort  between  scientists,  funders, 
industry, regulators and clinicians, I believe they can be 
overcome.
Where can I go for more information?
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